Phase I dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an inhaled recombinant human ACE2.

Martin BauerAnselm JordaValentin Al-JalaliMichael Wölfl-DuchekFelix BergmannAlina Nussbaumer-PröllAriane SteindlRomana GugenbergerSarah BischofDoris WimmerMarco IdzkoMarkus Zeitlinger

Published in: ERJ open research (2024)

The application of aerosolised APN01 is safe and well tolerated after single and multiple doses. By achieving a high local concentration in the lungs and low systemic bioavailability, inhaled rhACE2 may present a therapeutic option in ACE2-related diseases.

Keyphrases

recombinant human
open label
cystic fibrosis
angiotensin converting enzyme
angiotensin ii
randomized controlled trial